Volume 122, Issue 4 , Pages 803-810, October 2008
Modulation of β1-integrins on hemopoietic progenitor cells after allergen challenge in asthmatic subjects
Background
Mobilization of hemopoietic progenitor cells from the bone marrow (BM) is a feature of inflammatory asthmatic responses. Understanding the mechanisms regulating progenitor cell mobilization and trafficking to the peripheral circulation might be important for the development of effective asthma therapies.
Objective
We investigated the role of adhesion molecules in the mobilization of hemopoietic progenitor cells from the BM during an allergen-induced asthmatic response.
Methods
BM and peripheral blood samples were obtained from dual-responders with mild asthma before and at several time points after allergen challenge. Fluctuations in expression and adhesive properties of β1- and β2-integrins on CD34+CD45+ progenitor cells were assessed by using flow cytometry and adhesion to protein-coated wells, respectively.
Results
On BM-derived CD34+CD45+ cells, expression of very late antigen (VLA) 4, but not VLA-5 or Mac-1, decreased significantly 24 hours after allergen challenge and had begun to recover by 48 hours after challenge. In peripheral blood allergen challenge induced a significant decrease in VLA-4 levels after 6 hours, which had not recovered by 96 hours after challenge. Similarly, VLA-5 expression decreased, most prominently at 72 to 96 hours after allergen challenge. In contrast, Mac-1 levels did not change. Chemokine-stimulated adhesion of BM-derived CD34+CD45+ cells to fibronectin was significantly attenuated 24 hours after challenge. Furthermore, adhesion to fibronectin and vascular cell adhesion molecule 1 was greatly reduced by anti-VLA-4 or anti-VLA-5 antibodies.
Conclusions
Preferential downregulation of β1-integrin expression on progenitor cells can reduce the tethering forces to BM components, thus facilitating their egress to the peripheral circulation during an allergic inflammatory response.
Key words: Adhesion, integrins, fibronectin, vascular cell adhesion molecule 1, egress, mobilization, asthma, allergen, inflammation
Abbreviations used: BM, Bone marrow, LFA, Leukocyte function–associated antigen, PB, peripheral blood, SDF, Stromal cell–derived factor, SMFI, Specific mean fluorescence intensity, VCAM, Vascular cell adhesion molecule, VLA, Very late antigen
Supported by a grant from the Canadian Institutes of Health Research and an educational grant from AstraZeneca, United Kingdom. Adriana Catalli holds a Father Sean O'Sullivan Postdoctoral Fellowship award.
Disclosure of potential conflict of interest: P. Newbold, R. I. Craggs, and M. Foster are employed by AstraZeneca. P. M. O'Byrne has received research support from AstraZeneca, Altana, Bolipox, GlaxoSmithKline, MedImmune, Merck, Pfizer, Wyeta, Nycomed, Topigen, and Resistencia. R. Sehmi has received research support from GlaxoSmithKline; has served as a member of the American Academy of Allergy, Asthma & Immunology (AAAAI); and has presented on behalf of the AAAAI. The rest of the authors have declared that they have no conflicts of interest.
PII: S0091-6749(08)01350-X
doi:10.1016/j.jaci.2008.07.021
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 122, Issue 4 , Pages 803-810, October 2008
